Markets are sending mixed signals today. Analysts split on tech, short sellers swarm biotech, and the calendar points squarely at NVDA next week.
NVIDIA got a fresh analyst bump, with the consensus target nudging to $271.36. Fifty-five buy ratings back the $5.4 trillion chip giant. Cisco took the opposite hit. Analysts cut the average target from $105.68 to $91.36 — a $14 drop — citing AI infrastructure competition. The divergence reflects a broader theme: the market rewards AI winners and punishes those struggling to adapt.
Bears are piling into small-cap healthcare names at an unusual rate. Wolfspeed has 80.1% of its float sold short, up 22.5 points in one week. Zero shares remain available to borrow. Chemomab Therapeutics hit 91.83% utilization — near its 52-week peak. is at 90.91% utilization ahead of earnings tomorrow. The pattern is clear: short sellers are pressing hard into small healthcare names with thin floats and tight borrow supply.
Kraft Heinz CEO Steve Cahillane made the most notable insider purchase — nearly $5M at $23.46, filed May 13. That's a direct bet on a beaten-down stock. On the sell side, Solaris Energy Infrastructure insiders filed close to $290M in combined sales. CFOs at DaVita, Comfort Systems USA, and AerCap each filed sales near $10M.
The week's biggest event is NVIDIA's Q1 2027 results on May 20. With AI spending still the market's core narrative, the print will set the tone for tech broadly. US 30-year bond yields meanwhile hit 5% — the first time since 2007 — adding pressure on growth valuations heading into the week.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
